Clinical trial Recruiting at 1 site Phase 4 Interventional Ages 18 and up

Cervicothoracic Sympathetic Block for Post-CCOVID Condition

Official title: A Randomized Controlled Trial for Cervicothoracic Sympathetic Chain Block Against Placebo Saline Injection Evaluation for Post COVID Condition: the CeASE RCT

Run by University Health Network, Toronto · NCT07468604 · Data updated 2026-11-12

This study tests whether a cervicothoracic sympathetic block with local anesthetic can help people who have ongoing post-CCOVID symptoms.

Quick facts

PhasePhase 4
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment78 (estimated)
SponsorUniversity Health Network, Toronto
Academic / other
Locations2 sites (Toronto, Ontario and 1 other locations)
StatusRecruiting
StartedMay 19, 2026
Main results expectedMay 20, 2027
Study endsSeptember 1, 2027
Registry record updatedOctober 9, 2026
Trial IDNCT07468604 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18 or older with PCC symptoms lasting at least three months and measurable autonomic dysfunction (COMPASS-31 > 0), stable on PCC medications for at least four weeks.

Probably not a fit

Patients without autonomic involvement or who do not respond to the block may see no benefit and could experience procedure-related risks.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 4 interventional trial investigates whether a cervicothoracic sympathetic block improves autonomic symptoms in adults with post-COVID condition. Participants receive 5 mL of 0.25% bupivacaine with epinephrine or saline placebo at the injection site, with randomization and standard safety monitoring. Eligibility focuses on adults with PCC lasting at least three months and measurable autonomic symptoms, who are stable on PCC-related medications. The trial is conducted at two Toronto sites under the University Health Network. Outcomes are expected to inform whether this targeted nerve block can relieve dysautonomia-related PCC symptoms and guide future therapy development.

Why it matters

Potential benefit: If successful, patients may experience reduced autonomic symptoms and improved daily function.

How similar studies have gone: Prior studies of sympatholytic or neuromodulatory approaches in PCC or autonomic dysfunction have shown mixed results; this trial explores a direct local blockade as a novel approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion criteria

1. Age 18 years or older
2. PCC following COVID-19 infection with symptoms lasting for at least three months
3. Ability to read, write, and understand English
4. Quantified autonomic symptoms from at least one domain as reported by the patient on the screener Composite Autonomic Symptom Score (COMPASS-31), i.e. a COMPASS-31 score greater than 0. COMPASS-31 assesses 6 domains of autonomic symptoms: Orthostatic Intolerance, Vasomotor, Secretomotor, Gastrointestinal, Bladder, and Pupillomotor.
5. Patients should be stable on any PCC-related medications for at least four weeks.

Exclusion criteria

1. History of co-existing conditions that are a contraindication for CSB:

   1. Unilateral vocal cord paralysis; Severe chronic obstructive pulmonary disease (FEV1 between 30-50% of predicted value)
   2. Recent myocardial infarction (within the last one year), Cardiac conduction block of any degree
   3. Glaucoma
   4. Infection or mass at injection site, bleeding disorders
2. Comorbid conditions that could confound study results, such as:

   1. Active autoimmune disorders
   2. Pre-existing autonomic dysfunction (e.g. POTS, IST, and CRPS) prior to COVID-19
   3. Untreated psychiatric conditions (e.g. severe anxiety or PTSD requiring medication adjustments during the study period)
3. Recent history of major surgery or cerebrovascular events within the last three months
4. Allergy to local anesthetic; Inability to extend the neck for any reason (e.g. severe arthritis)
5. History of prior stellate ganglion block

Where it's running

  • Toronto Western Hospital
    Toronto, Ontario, Canada
    Recruiting
  • Women's College Hospital
    Toronto, Ontario, Canada
    Not yet recruiting

Study contacts

  • Principal investigator: Anuj Bhatia, MD, PhD — University Health Network, Toronto
  • Study coordinator: Emad Al Azazi, MD, PhD
  • Email: emad.al-azazi@uhn.ca
  • Phone: 4166035800

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.